Amarin Corp Plc (AMRN)

[biotechtrader2020]

I agree with you on the CocaCola analogy from a market opportunity standpoint - i.e., the total addressable market is big.

However, that is where the analogy ends. Comparing CocaCola patents/trade secrets with drug companies is like comparing apples and oranges. Here, upon patent expiration, FDA has laid out guidelines for the generic companies to show bio equivalence and the competition will come in swift.

Blockbuster drugs often end up facing competitve threats before their patent expiration. Once cheaper generics come in, erosion in sales is inevitable.

Can you recall any blockbuster drug that has held its market share "after patent expiration and arrival of generics"?

To Summarize, AMRN's CocaCola comparison will end in 9 years out of which the next 2-3 years will involve heavy expenditure to grow revenues and to maintain competitive edge in a changing landscape.

I know you are a super-smart investor and you invested heavily around all-time lows (so you won't care about the price). The longs in this board with higher cost-basis will need lots of vascepa (due to share price fluctuation) if AMRN goes it alone. For this reason, I hope AMRN's management accepts a high offer.